Mogode OCV Booster dose Study (MOBS)

Grant number: 215663/Z/19/Z

Grant search

Key facts

  • Disease

    Cholera
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $477,018.59
  • Funder

    Wellcome Trust
  • Principal Investigator

    Prof. Jerome ATEUDJIEU
  • Research Location

    Cameroon
  • Lead Research Institution

    M.A. SANTE
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Problem statement: Oral cholera vaccine (OCV) protects for 3 to 5 years. The Cholera Roadmap suggests repeating vaccination after this interval; however, it is not known the number of vaccine doses to be used. Specific Aim: Determine if persons who received previous doses of OCV respond to a single dose of OCV with a booster response 2 or 3 years after the initial doses. Hypothesis. An initial immunization with two doses of OCV will prime individuals so that a single dose 2 to 3 years after the initial vaccinations will stimulate a booster response. Evidence of a booster response will be observed as an early rise in serum vibriocidal and IgA/IgG titers (day 4 or 5) following the single dose. Proposed Study. Subjects who had received zero, one or two doses of OCV during the Mogode 2017 OCV campaign will be given a single dose of OCV. Serum samples will be obtained prior to the dose, and on days 4 or 5, 7, and 14 (half on day 4/half on day 5). The subjects will be age stratified into 3 groups (1-4, 5-14, >14 years) and according to whether they had received zero, 1 or 2 doses earlier.